Home | Structured Search | Drug Resource
Find: within
Hepatitis A > Consultation for Management Author: Catherine M. Dentinger, FNP, MS; Brian J. McMahon, MD, MACP
Editorial changes - 2008-01-24
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Cholestasis has been reported as an occasional complication of hepatitis A.
  • Relapsing disease has been reported as an occasional complication in children and adults.
  • Fulminant hepatitis A is a rare complication of HAV infection.

Evidence:

  • In one study of hospitalized patients with hepatitis A, cholestasis was documented in 4 of 59 (7%) patients (78).
  • A short course of corticosteroids in patients with severe cholestasis may reduce the severity of symptoms and decrease bilirubin levels (106).
  • Detection of plasma HAV RNA after 20 days of illness may predict a prolonged course of hepatitis A (107).
  • Relapsing hepatitis A occurs in approximately 3% to 20% of patients with acute hepatitis A (87).
  • Approximately 8% of the 2000 cases of fulminant hepatitis in the U.S. are due to hepatitis A (98).
  • Of the approximately 7% of liver transplants performed for fulminant hepatic failure, approximately 7% are due to fulminant HAV infection (98).

Comments:

  • Cases of relapsing hepatitis A generally resolve without sequelae.
  • The severity of hepatitis A increases with age.
  • Persons with underlying chronic disease are more likely to have severe disease.

FAQs
Brian J. McMahon, MD, MACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Catherine M. Dentinger, FNP, MS has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2008 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.